C H AM BERL AI N U N I VERSI TY | 2 02 6 -2 02 7
NR 566 Advanced
Pharmacology for
Care of the Family
Comprehensive Final Examination covering
pharmacokinetics, pharmacodynamics, cardiovascular
pharmacology, antimicrobial stewardship, endocrine
therapeutics, neuropharmacology, pain management,
and special population prescribing across 160 verified
questions with detailed clinical rationales.
160 Questions | 10 Sections | Complete with Rationales
Aligned with 2026-2027 NR566 Curriculum Standards
N R 5 6 6 F I N A L E X A M I N AT I O N | A C T U A L E X A M C O M P L E T E 1 6 0 Q U E S T I O N S
,Advanced Pharmacokinetics and Pharmacodynamics
Q1: A 55-year-old patient with atrial fibrillation is prescribed warfarin. Genetic testing reveals the
patient is a CYP2C19 poor metabolizer and carries the VKORC1 A/A genotype. Which of the following is
the most appropriate clinical consideration based on these pharmacogenomic findings?
A. The patient will require higher-than-average warfarin doses to achieve therapeutic INR
B. CYP2C19 genotype has no impact on warfarin metabolism and no dose adjustment is needed
C. The patient is at increased risk for warfarin sensitivity and should be started on a lower initial dose
(2-3 mg daily) [CORRECT]
D. The patient should be switched to clopidogrel due to CYP2C19 poor metabolizer status
Correct Answer: C
Rationale: The VKORC1 A/A genotype is associated with reduced VKORC1 enzyme expression, leading to increased warfarin
sensitivity and lower dose requirements (2-3 mg/day) per CPIC guidelines. Warfarin is primarily metabolized by CYP2C9 (not
CYP2C19), though CYP2C19 polymorphisms can still have minor effects on overall drug metabolism. Clopidogrel, not warfarin, is
the drug most affected by CYP2C19 poor metabolizer status (reduced prodrug activation). Chamberlain NR566 pharmacogenomics
content emphasizes VKORC1 and CYP2C9 as the primary genetic determinants of warfarin dosing.
Q2: A patient taking sertraline (a CYP2D6 substrate) is prescribed tramadol for chronic pain. The
patient reports experiencing profound sedation, dizziness, and nausea. Which pharmacokinetic
mechanism best explains this interaction?
A. Sertraline induces CYP2D6, leading to accelerated tramadol metabolism and accumulation of toxic
metabolites
B. Sertraline is a moderate CYP2D6 inhibitor, reducing conversion of tramadol to its active metabolite
O-desmethyltramadol, but increasing tramadol parent drug levels and serotonergic effects [CORRECT]
C. Tramadol induces CYP3A4, reducing sertraline efficacy and causing withdrawal-like symptoms
D. Both drugs compete for CYP3A4 metabolism, leading to decreased renal clearance of both agents
Correct Answer: B
Rationale: Sertraline is a moderate CYP2D6 inhibitor that reduces the conversion of tramadol (a prodrug) to its active metabolite
O-desmethyltramadol (M1). However, the parent drug tramadol still has serotonergic and mu-opioid receptor activity. The inhibition
leads to higher tramadol levels, increasing sedation and nausea. CYP3A4 is not the primary pathway here. CYP2D6 is the key
enzyme, and this is a classic NR566 drug interaction scenario emphasizing the importance of understanding CYP450 inhibition
patterns.
Q3: A drug has a half-life of 6 hours. If a 200 mg dose is administered intravenously, approximately how
many hours will it take for the plasma concentration to reach approximately 12.5 mg (steady-state
elimination to ~6.25% of the original concentration)?
A. 12 hours
B. 24 hours [CORRECT]
C. 18 hours
D. 36 hours
Correct Answer: B
Rationale: After each half-life, 50% of the remaining drug is eliminated. Starting at 200 mg: at 6 hours (1 half-life) = 100 mg
(50%); at 12 hours (2 half-lives) = 50 mg (25%); at 18 hours (3 half-lives) = 25 mg (12.5%); at 24 hours (4 half-lives) = 12.5 mg
(6.25%). Therefore, 12.5 mg is reached after exactly 4 half-lives × 6 hours = 24 hours. Option A (12 hours) yields 50 mg, option C
(18 hours) yields 25 mg, and option D (36 hours, 6 half-lives) would yield only ~3.1 mg. Per NR566 pharmacokinetics content,
students must master half-life elimination calculations using the 50% rule across successive half-lives, applying the formula:
remaining drug = initial dose × (0.5)^n where n is the number of half-lives elapsed.
,NR 566 Final Exam | Advanced Pharmacology for Care of the Family | 2026/2027
Q4: A 28-year-old woman who has been taking oral contraceptive pills (OCPs) for 5 years presents with
an unplanned pregnancy. She recently started taking St. John's Wort for depression 3 months ago.
Which pharmacokinetic mechanism explains this contraceptive failure?
A. St. John's Wort induces CYP3A4 and P-glycoprotein, accelerating the metabolism of estrogen and
progestin components of OCPs, reducing their bioavailability [CORRECT]
B. St. John's Wort inhibits CYP3A4, increasing estrogen and progestin levels and causing hormone toxicity
C. St. John's Wort increases protein binding of contraceptive hormones, reducing free drug levels
D. St. John's Wort decreases renal clearance of contraceptive hormones, leading to accumulation and feedback
inhibition of ovulation
Correct Answer: A
Rationale: St. John's Wort (Hypericum perforatum) is a potent CYP3A4 inducer and also induces P-glycoprotein (P-gp). Oral
contraceptive estrogen and progestin components are metabolized by CYP3A4, so induction leads to increased metabolic clearance
and reduced bioavailability, causing contraceptive failure. This is a well-documented NR566 drug interaction. St. John's Wort is an
inducer, NOT an inhibitor. It does not increase protein binding or decrease renal clearance of OCP hormones. Chamberlain NR566
emphasizes CYP3A4 inducers as a critical cause of OCP failure.
Q5: A 72-year-old patient with heart failure is being considered for digoxin therapy. The patient's serum
creatinine is 1.8 mg/dL, weight is 60 kg. Estimated creatinine clearance is approximately 30 mL/min.
Which dosing modification is most appropriate?
A. No dose adjustment is needed because digoxin is primarily metabolized hepatically
B. Digoxin should be avoided entirely in any patient with a creatinine clearance below 50 mL/min
C. The dose should be increased because decreased protein binding in elderly patients reduces free drug levels
D. The dose should be reduced and extended interval dosing should be considered due to decreased renal
clearance of digoxin [CORRECT]
Correct Answer: D
Rationale: Digoxin is primarily eliminated renally (~80% unchanged), so reduced creatinine clearance (30 mL/min) necessitates
dose reduction to avoid toxicity. In elderly patients with CKD, digoxin accumulation can cause life-threatening arrhythmias, nausea,
and visual disturbances. The typical approach is lower doses (0.125 mg daily or every other day) with therapeutic drug monitoring
(target trough 0.5-0.9 ng/mL). Digoxin is NOT primarily metabolized hepatically. While reduced protein binding does occur in
elderly patients, this would increase (not decrease) free drug levels, further supporting the need for dose reduction. Per NR566 and
ACC/AHA guidelines, digoxin is not absolutely contraindicated at CrCl <50 but requires careful dose adjustment and monitoring.
Q6: A 45-year-old patient with depression is prescribed a medication that undergoes extensive first-pass
metabolism with a bioavailability of only 10%. If the desired therapeutic plasma concentration requires
50 mg of drug to reach the systemic circulation, what oral dose should be prescribed?
A. 5 mg
B. 50 mg
C. 500 mg [CORRECT]
D. 250 mg
Correct Answer: C
Rationale: Bioavailability (F) = (amount reaching systemic circulation) / (administered dose) × 100%. Therefore: Administered dose
= desired systemic amount / F = 50 mg / 0.10 = 500 mg. First-pass metabolism in the liver significantly reduces bioavailability for
drugs like propranolol, morphine, and verapamil. This is a core NR566 pharmacokinetics calculation. If only 10% of the oral dose
reaches systemic circulation, a much larger oral dose is needed compared to IV administration. Options A (5 mg) and B (50 mg) fail
to account for the 90% loss, while D (250 mg) would only account for 20% bioavailability.
Q7: A patient with HLA-B*5701 positive status presents to the clinic for HIV treatment initiation. Which
of the following medications is absolutely contraindicated in this patient?
A. Tenofovir
B. Dolutegravir
C. Emtricitabine
D. Abacavir [CORRECT]
160 Verified Questions | Chamberlain University Page 2 Complete with Rationales
, NR 566 Final Exam | Advanced Pharmacology for Care of the Family | 2026/2027
Correct Answer: D
Rationale: HLA-B*5701 is a pharmacogenomic marker strongly associated with abacavir hypersensitivity reaction, a potentially
fatal systemic reaction characterized by fever, rash, and multi-organ involvement. The FDA and clinical guidelines (DHHS)
mandate HLA-B*5701 screening before initiating abacavir. If positive, abacavir is absolutely contraindicated regardless of other
factors. Tenofovir, emtricitabine, and dolutegravir do not have HLA-B*5701-associated hypersensitivity. This is a hallmark
pharmacogenomics example emphasized in Chamberlain NR566 curriculum and is one of the most clinically validated
pharmacogenetic tests in routine practice.
Q8: A 60-year-old patient taking warfarin for DVT prophylaxis is started on amiodarone for atrial
fibrillation. The INR increases from 2.2 to 4.1 within 2 weeks. Which mechanism best explains this
interaction?
A. Amiodarone is a potent inhibitor of CYP2C9 and CYP3A4, reducing warfarin metabolism and
increasing anticoagulant effect [CORRECT]
B. Amiodarone induces CYP2C9, increasing warfarin metabolism and reducing INR
C. Amiodarone competes with warfarin for plasma protein binding sites, increasing free warfarin concentration
D. Amiodarone decreases vitamin K absorption from the GI tract, potentiating warfarin's effect
Correct Answer: A
Rationale: Amiodarone is a potent inhibitor of CYP2C9 (the primary enzyme responsible for S-warfarin metabolism) and also
inhibits CYP3A4 (R-warfarin metabolism). This dual inhibition significantly reduces warfarin clearance, leading to elevated INR
and increased bleeding risk. When amiodarone is added to warfarin, the warfarin dose typically needs to be reduced by 30-50%.
Amiodarone is an inhibitor, not an inducer, eliminating option B. While protein binding displacement can occur with some
interactions, the primary mechanism here is CYP inhibition. Amiodarone does not affect vitamin K absorption. Per NR566 content,
amiodarone-warfarin is a classic and clinically significant CYP450-mediated drug interaction that prescribers must anticipate and
manage proactively.
Q9: A patient with a known SLCO1B1 genetic variant (c.521T>C, rs4149056) is being considered for
high-intensity statin therapy with atorvastatin 80 mg. What is the primary clinical concern with this
pharmacogenomic profile?
A. The variant increases statin efficacy, requiring a lower dose for the same LDL reduction
B. The variant increases the risk of statin-induced hepatotoxicity but not myopathy
C. The variant has no clinical significance for statin therapy decisions
D. The variant reduces statin hepatic uptake via OATP1B1 transporter, increasing plasma statin
concentrations and risk of myopathy [CORRECT]
Correct Answer: D
Rationale: The SLCO1B1 c.521T>C variant reduces the function of the OATP1B1 hepatic uptake transporter, which is responsible
for moving statins from the blood into hepatocytes. Reduced hepatic uptake leads to higher plasma statin concentrations, increasing
the risk of statin-associated muscle symptoms (SAMS) and myopathy, particularly with high-intensity statin doses. CPIC guidelines
recommend considering a lower statin dose or alternative statin (e.g., rosuvastatin or lower-dose atorvastatin) in SLCO1B1 variant
carriers. The variant does NOT increase efficacy, and its primary concern is myopathy (not hepatotoxicity). This is a key
pharmacogenomics learning objective in Chamberlain NR566.
Q10: A 35-year-old patient is prescribed a highly protein-bound drug (98% bound to albumin). A second
drug that is also highly protein-bound is added to the regimen. Which of the following best describes the
clinical significance of this interaction?
A. The displacement interaction will cause a dramatic, sustained increase in free drug concentration because total
drug levels decrease proportionally
B. Protein binding displacement is always clinically significant and requires immediate dose reduction of both
drugs
C. The displacement interaction causes a transient increase in free drug concentration, but increased
clearance typically compensates quickly, making this interaction rarely clinically significant unless the
displaced drug has a narrow therapeutic index [CORRECT]
D. Highly protein-bound drugs cannot be displaced because albumin binding sites are specific to each drug
Correct Answer: C
160 Verified Questions | Chamberlain University Page 3 Complete with Rationales
NR 566 Advanced
Pharmacology for
Care of the Family
Comprehensive Final Examination covering
pharmacokinetics, pharmacodynamics, cardiovascular
pharmacology, antimicrobial stewardship, endocrine
therapeutics, neuropharmacology, pain management,
and special population prescribing across 160 verified
questions with detailed clinical rationales.
160 Questions | 10 Sections | Complete with Rationales
Aligned with 2026-2027 NR566 Curriculum Standards
N R 5 6 6 F I N A L E X A M I N AT I O N | A C T U A L E X A M C O M P L E T E 1 6 0 Q U E S T I O N S
,Advanced Pharmacokinetics and Pharmacodynamics
Q1: A 55-year-old patient with atrial fibrillation is prescribed warfarin. Genetic testing reveals the
patient is a CYP2C19 poor metabolizer and carries the VKORC1 A/A genotype. Which of the following is
the most appropriate clinical consideration based on these pharmacogenomic findings?
A. The patient will require higher-than-average warfarin doses to achieve therapeutic INR
B. CYP2C19 genotype has no impact on warfarin metabolism and no dose adjustment is needed
C. The patient is at increased risk for warfarin sensitivity and should be started on a lower initial dose
(2-3 mg daily) [CORRECT]
D. The patient should be switched to clopidogrel due to CYP2C19 poor metabolizer status
Correct Answer: C
Rationale: The VKORC1 A/A genotype is associated with reduced VKORC1 enzyme expression, leading to increased warfarin
sensitivity and lower dose requirements (2-3 mg/day) per CPIC guidelines. Warfarin is primarily metabolized by CYP2C9 (not
CYP2C19), though CYP2C19 polymorphisms can still have minor effects on overall drug metabolism. Clopidogrel, not warfarin, is
the drug most affected by CYP2C19 poor metabolizer status (reduced prodrug activation). Chamberlain NR566 pharmacogenomics
content emphasizes VKORC1 and CYP2C9 as the primary genetic determinants of warfarin dosing.
Q2: A patient taking sertraline (a CYP2D6 substrate) is prescribed tramadol for chronic pain. The
patient reports experiencing profound sedation, dizziness, and nausea. Which pharmacokinetic
mechanism best explains this interaction?
A. Sertraline induces CYP2D6, leading to accelerated tramadol metabolism and accumulation of toxic
metabolites
B. Sertraline is a moderate CYP2D6 inhibitor, reducing conversion of tramadol to its active metabolite
O-desmethyltramadol, but increasing tramadol parent drug levels and serotonergic effects [CORRECT]
C. Tramadol induces CYP3A4, reducing sertraline efficacy and causing withdrawal-like symptoms
D. Both drugs compete for CYP3A4 metabolism, leading to decreased renal clearance of both agents
Correct Answer: B
Rationale: Sertraline is a moderate CYP2D6 inhibitor that reduces the conversion of tramadol (a prodrug) to its active metabolite
O-desmethyltramadol (M1). However, the parent drug tramadol still has serotonergic and mu-opioid receptor activity. The inhibition
leads to higher tramadol levels, increasing sedation and nausea. CYP3A4 is not the primary pathway here. CYP2D6 is the key
enzyme, and this is a classic NR566 drug interaction scenario emphasizing the importance of understanding CYP450 inhibition
patterns.
Q3: A drug has a half-life of 6 hours. If a 200 mg dose is administered intravenously, approximately how
many hours will it take for the plasma concentration to reach approximately 12.5 mg (steady-state
elimination to ~6.25% of the original concentration)?
A. 12 hours
B. 24 hours [CORRECT]
C. 18 hours
D. 36 hours
Correct Answer: B
Rationale: After each half-life, 50% of the remaining drug is eliminated. Starting at 200 mg: at 6 hours (1 half-life) = 100 mg
(50%); at 12 hours (2 half-lives) = 50 mg (25%); at 18 hours (3 half-lives) = 25 mg (12.5%); at 24 hours (4 half-lives) = 12.5 mg
(6.25%). Therefore, 12.5 mg is reached after exactly 4 half-lives × 6 hours = 24 hours. Option A (12 hours) yields 50 mg, option C
(18 hours) yields 25 mg, and option D (36 hours, 6 half-lives) would yield only ~3.1 mg. Per NR566 pharmacokinetics content,
students must master half-life elimination calculations using the 50% rule across successive half-lives, applying the formula:
remaining drug = initial dose × (0.5)^n where n is the number of half-lives elapsed.
,NR 566 Final Exam | Advanced Pharmacology for Care of the Family | 2026/2027
Q4: A 28-year-old woman who has been taking oral contraceptive pills (OCPs) for 5 years presents with
an unplanned pregnancy. She recently started taking St. John's Wort for depression 3 months ago.
Which pharmacokinetic mechanism explains this contraceptive failure?
A. St. John's Wort induces CYP3A4 and P-glycoprotein, accelerating the metabolism of estrogen and
progestin components of OCPs, reducing their bioavailability [CORRECT]
B. St. John's Wort inhibits CYP3A4, increasing estrogen and progestin levels and causing hormone toxicity
C. St. John's Wort increases protein binding of contraceptive hormones, reducing free drug levels
D. St. John's Wort decreases renal clearance of contraceptive hormones, leading to accumulation and feedback
inhibition of ovulation
Correct Answer: A
Rationale: St. John's Wort (Hypericum perforatum) is a potent CYP3A4 inducer and also induces P-glycoprotein (P-gp). Oral
contraceptive estrogen and progestin components are metabolized by CYP3A4, so induction leads to increased metabolic clearance
and reduced bioavailability, causing contraceptive failure. This is a well-documented NR566 drug interaction. St. John's Wort is an
inducer, NOT an inhibitor. It does not increase protein binding or decrease renal clearance of OCP hormones. Chamberlain NR566
emphasizes CYP3A4 inducers as a critical cause of OCP failure.
Q5: A 72-year-old patient with heart failure is being considered for digoxin therapy. The patient's serum
creatinine is 1.8 mg/dL, weight is 60 kg. Estimated creatinine clearance is approximately 30 mL/min.
Which dosing modification is most appropriate?
A. No dose adjustment is needed because digoxin is primarily metabolized hepatically
B. Digoxin should be avoided entirely in any patient with a creatinine clearance below 50 mL/min
C. The dose should be increased because decreased protein binding in elderly patients reduces free drug levels
D. The dose should be reduced and extended interval dosing should be considered due to decreased renal
clearance of digoxin [CORRECT]
Correct Answer: D
Rationale: Digoxin is primarily eliminated renally (~80% unchanged), so reduced creatinine clearance (30 mL/min) necessitates
dose reduction to avoid toxicity. In elderly patients with CKD, digoxin accumulation can cause life-threatening arrhythmias, nausea,
and visual disturbances. The typical approach is lower doses (0.125 mg daily or every other day) with therapeutic drug monitoring
(target trough 0.5-0.9 ng/mL). Digoxin is NOT primarily metabolized hepatically. While reduced protein binding does occur in
elderly patients, this would increase (not decrease) free drug levels, further supporting the need for dose reduction. Per NR566 and
ACC/AHA guidelines, digoxin is not absolutely contraindicated at CrCl <50 but requires careful dose adjustment and monitoring.
Q6: A 45-year-old patient with depression is prescribed a medication that undergoes extensive first-pass
metabolism with a bioavailability of only 10%. If the desired therapeutic plasma concentration requires
50 mg of drug to reach the systemic circulation, what oral dose should be prescribed?
A. 5 mg
B. 50 mg
C. 500 mg [CORRECT]
D. 250 mg
Correct Answer: C
Rationale: Bioavailability (F) = (amount reaching systemic circulation) / (administered dose) × 100%. Therefore: Administered dose
= desired systemic amount / F = 50 mg / 0.10 = 500 mg. First-pass metabolism in the liver significantly reduces bioavailability for
drugs like propranolol, morphine, and verapamil. This is a core NR566 pharmacokinetics calculation. If only 10% of the oral dose
reaches systemic circulation, a much larger oral dose is needed compared to IV administration. Options A (5 mg) and B (50 mg) fail
to account for the 90% loss, while D (250 mg) would only account for 20% bioavailability.
Q7: A patient with HLA-B*5701 positive status presents to the clinic for HIV treatment initiation. Which
of the following medications is absolutely contraindicated in this patient?
A. Tenofovir
B. Dolutegravir
C. Emtricitabine
D. Abacavir [CORRECT]
160 Verified Questions | Chamberlain University Page 2 Complete with Rationales
, NR 566 Final Exam | Advanced Pharmacology for Care of the Family | 2026/2027
Correct Answer: D
Rationale: HLA-B*5701 is a pharmacogenomic marker strongly associated with abacavir hypersensitivity reaction, a potentially
fatal systemic reaction characterized by fever, rash, and multi-organ involvement. The FDA and clinical guidelines (DHHS)
mandate HLA-B*5701 screening before initiating abacavir. If positive, abacavir is absolutely contraindicated regardless of other
factors. Tenofovir, emtricitabine, and dolutegravir do not have HLA-B*5701-associated hypersensitivity. This is a hallmark
pharmacogenomics example emphasized in Chamberlain NR566 curriculum and is one of the most clinically validated
pharmacogenetic tests in routine practice.
Q8: A 60-year-old patient taking warfarin for DVT prophylaxis is started on amiodarone for atrial
fibrillation. The INR increases from 2.2 to 4.1 within 2 weeks. Which mechanism best explains this
interaction?
A. Amiodarone is a potent inhibitor of CYP2C9 and CYP3A4, reducing warfarin metabolism and
increasing anticoagulant effect [CORRECT]
B. Amiodarone induces CYP2C9, increasing warfarin metabolism and reducing INR
C. Amiodarone competes with warfarin for plasma protein binding sites, increasing free warfarin concentration
D. Amiodarone decreases vitamin K absorption from the GI tract, potentiating warfarin's effect
Correct Answer: A
Rationale: Amiodarone is a potent inhibitor of CYP2C9 (the primary enzyme responsible for S-warfarin metabolism) and also
inhibits CYP3A4 (R-warfarin metabolism). This dual inhibition significantly reduces warfarin clearance, leading to elevated INR
and increased bleeding risk. When amiodarone is added to warfarin, the warfarin dose typically needs to be reduced by 30-50%.
Amiodarone is an inhibitor, not an inducer, eliminating option B. While protein binding displacement can occur with some
interactions, the primary mechanism here is CYP inhibition. Amiodarone does not affect vitamin K absorption. Per NR566 content,
amiodarone-warfarin is a classic and clinically significant CYP450-mediated drug interaction that prescribers must anticipate and
manage proactively.
Q9: A patient with a known SLCO1B1 genetic variant (c.521T>C, rs4149056) is being considered for
high-intensity statin therapy with atorvastatin 80 mg. What is the primary clinical concern with this
pharmacogenomic profile?
A. The variant increases statin efficacy, requiring a lower dose for the same LDL reduction
B. The variant increases the risk of statin-induced hepatotoxicity but not myopathy
C. The variant has no clinical significance for statin therapy decisions
D. The variant reduces statin hepatic uptake via OATP1B1 transporter, increasing plasma statin
concentrations and risk of myopathy [CORRECT]
Correct Answer: D
Rationale: The SLCO1B1 c.521T>C variant reduces the function of the OATP1B1 hepatic uptake transporter, which is responsible
for moving statins from the blood into hepatocytes. Reduced hepatic uptake leads to higher plasma statin concentrations, increasing
the risk of statin-associated muscle symptoms (SAMS) and myopathy, particularly with high-intensity statin doses. CPIC guidelines
recommend considering a lower statin dose or alternative statin (e.g., rosuvastatin or lower-dose atorvastatin) in SLCO1B1 variant
carriers. The variant does NOT increase efficacy, and its primary concern is myopathy (not hepatotoxicity). This is a key
pharmacogenomics learning objective in Chamberlain NR566.
Q10: A 35-year-old patient is prescribed a highly protein-bound drug (98% bound to albumin). A second
drug that is also highly protein-bound is added to the regimen. Which of the following best describes the
clinical significance of this interaction?
A. The displacement interaction will cause a dramatic, sustained increase in free drug concentration because total
drug levels decrease proportionally
B. Protein binding displacement is always clinically significant and requires immediate dose reduction of both
drugs
C. The displacement interaction causes a transient increase in free drug concentration, but increased
clearance typically compensates quickly, making this interaction rarely clinically significant unless the
displaced drug has a narrow therapeutic index [CORRECT]
D. Highly protein-bound drugs cannot be displaced because albumin binding sites are specific to each drug
Correct Answer: C
160 Verified Questions | Chamberlain University Page 3 Complete with Rationales
